Literature DB >> 28475283

CD69: from activation marker to metabolic gatekeeper.

Danay Cibrián1,2,3, Francisco Sánchez-Madrid1,2,3.   

Abstract

CD69 is a membrane-bound, type II C-lectin receptor. It is a classical early marker of lymphocyte activation due to its rapid appearance on the surface of the plasma membrane after stimulation. CD69 is expressed by several subsets of tissue resident immune cells, including resident memory T (TRM) cells and gamma delta (γδ) T cells, and is therefore considered a marker of tissue retention. Recent evidence has revealed that CD69 regulates some specific functions of selected T-cell subsets, determining the migration-retention ratio as well as the acquisition of effector or regulatory phenotypes. Specifically, CD69 regulates the differentiation of regulatory T (Treg) cells as well as the secretion of IFN-γ, IL-17, and IL-22. The identification of putative CD69 ligands, such as Galectin-1 (Gal-1), suggests that CD69-induced signaling can be regulated not only during cognate contacts between T cells and antigen-presenting cells in lymphoid organs, but also in the periphery, where cytokines and other metabolites control the final outcome of the immune response. Here, we will discuss new aspects of the molecular signaling mediated by CD69 and its involvement in the metabolic reprogramming regulating TH-effector lineages.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD69; Galectin-1; LAT1; Metabolism; S1P1; T cells; mTOR

Mesh:

Substances:

Year:  2017        PMID: 28475283      PMCID: PMC6485631          DOI: 10.1002/eji.201646837

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  62 in total

1.  Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice.

Authors:  P Lauzurica; D Sancho; M Torres; B Albella; M Marazuela; T Merino; J A Bueren; C Martínez-A; F Sánchez-Madrid
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

2.  The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression.

Authors:  Toshinori Nakayama; Deborah J Kasprowicz; Masakatsu Yamashita; Lisa A Schubert; Geoffery Gillard; Motoko Kimura; Arnaud Didierlaurent; Haruhiko Koseki; Steven F Ziegler
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death.

Authors:  Marta A Toscano; Germán A Bianco; Juan M Ilarregui; Diego O Croci; Jorge Correale; Joseph D Hernandez; Norberto W Zwirner; Francoise Poirier; Eleanor M Riley; Linda G Baum; Gabriel A Rabinovich
Journal:  Nat Immunol       Date:  2007-06-24       Impact factor: 25.606

4.  A potential role for CD69 in thymocyte emigration.

Authors:  Chiguang Feng; Kenneth J Woodside; Barbara A Vance; Dalal El-Khoury; Matilde Canelles; Jan Lee; Ronald Gress; B J Fowlkes; Elizabeth W Shores; Paul E Love
Journal:  Int Immunol       Date:  2002-06       Impact factor: 4.823

5.  CD69 surface expression on human lung eosinophils after segmental allergen provocation.

Authors:  P Julius; W Luttmann; B Knoechel; C Kroegel; H Matthys; J C Virchow
Journal:  Eur Respir J       Date:  1999-06       Impact factor: 16.671

6.  Expansion of activated eosinophils in infants with severe atopic dermatitis.

Authors:  Tomoko Toma; Kazunori Mizuno; Hiroyuki Okamoto; Chiharu Kanegane; Kazuhide Ohta; Yasuhiro Ikawa; Masayoshi Miura; Mondo Kuroda; Yo Niida; Shoichi Koizumi; Akihiro Yachie
Journal:  Pediatr Int       Date:  2005-02       Impact factor: 1.524

7.  CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.

Authors:  David Sancho; Manuel Gómez; Fernando Viedma; Enric Esplugues; Mónica Gordón-Alonso; María Angeles García-López; Hortensia de la Fuente; Carlos Martínez-A; Pilar Lauzurica; Francisco Sánchez-Madrid
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor.

Authors:  Francisco J Quintana; Alexandre S Basso; Antonio H Iglesias; Thomas Korn; Mauricio F Farez; Estelle Bettelli; Mario Caccamo; Mohamed Oukka; Howard L Weiner
Journal:  Nature       Date:  2008-03-23       Impact factor: 49.962

9.  CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs.

Authors:  Lawrence R Shiow; David B Rosen; Nadezda Brdicková; Ying Xu; Jinping An; Lewis L Lanier; Jason G Cyster; Mehrdad Matloubian
Journal:  Nature       Date:  2006-03-08       Impact factor: 49.962

10.  Enhanced antitumor immunity in mice deficient in CD69.

Authors:  Enric Esplugues; David Sancho; Javier Vega-Ramos; Carlos Martínez; Uta Syrbe; Alf Hamann; Pablo Engel; Francisco Sánchez-Madrid; Pilar Lauzurica
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

View more
  184 in total

1.  The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.

Authors:  Huijun Zhao; Juan Ma; Ting Lei; Wanru Ma; Man Zhang
Journal:  Invest New Drugs       Date:  2018-10-29       Impact factor: 3.850

2.  A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.

Authors:  Gisela M Vaitaitis; Martin G Yussman; David H Wagner
Journal:  J Neuroimmunol       Date:  2019-03-21       Impact factor: 3.478

3.  Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis.

Authors:  Eduardo Beltrán; Lisa Ann Gerdes; Julia Hansen; Andrea Flierl-Hecht; Stefan Krebs; Helmut Blum; Birgit Ertl-Wagner; Frederik Barkhof; Tania Kümpfel; Reinhard Hohlfeld; Klaus Dornmair
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

Review 4.  Tissue-Resident Lymphocytes in the Kidney.

Authors:  Jan-Eric Turner; Martina Becker; Hans-Willi Mittrücker; Ulf Panzer
Journal:  J Am Soc Nephrol       Date:  2017-11-01       Impact factor: 10.121

Review 5.  Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.

Authors:  Abhishek D Garg; Sanket More; Nicole Rufo; Odeta Mece; Maria Livia Sassano; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

6.  Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

Authors:  Marina Wierz; Sandrine Pierson; Léa Guyonnet; Elodie Viry; Audrey Lequeux; Anaïs Oudin; Simone P Niclou; Markus Ollert; Guy Berchem; Bassam Janji; Coralie Guérin; Jerome Paggetti; Etienne Moussay
Journal:  Blood       Date:  2018-02-13       Impact factor: 22.113

7.  Salmonella Persist in Activated Macrophages in T Cell-Sparse Granulomas but Are Contained by Surrounding CXCR3 Ligand-Positioned Th1 Cells.

Authors:  Michael F Goldberg; Elizabeth K Roeske; Lauren N Ward; Thomas Pengo; Thamotharampillai Dileepan; Dmitri I Kotov; Marc K Jenkins
Journal:  Immunity       Date:  2018-12-11       Impact factor: 31.745

Review 8.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

Review 9.  Human T Cell Development, Localization, and Function throughout Life.

Authors:  Brahma V Kumar; Thomas J Connors; Donna L Farber
Journal:  Immunity       Date:  2018-02-20       Impact factor: 31.745

10.  DOCK2 Sets the Threshold for Entry into the Virtual Memory CD8+ T Cell Compartment by Negatively Regulating Tonic TCR Triggering.

Authors:  Vinay S Mahajan; Ezana Demissie; Faisal Alsufyani; Sudha Kumari; Grace J Yuen; Vinayak Viswanadham; Andrew Huang; Johnson Q Tran; James J Moon; Darrell J Irvine; Shiv Pillai
Journal:  J Immunol       Date:  2019-11-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.